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Abstract Typical (TCs) and atypical carcinoids (ACs) are
defined based on morphological criteria, and no grading
system is currently accepted to further stratify these enti-
ties. The 2015 WHO classification restricts the Ki-67 role
to biopsy or cytology samples, rather than for prognostic
prediction. We aimed to investigate whether values and
patterns of Ki-67 alone would allow for a clinically mean-
ingful stratification of lung carcinoids, regardless of
histological typing. Ki-67 proliferation index and pattern
(homogeneous versus heterogeneous expression) were
assessed in a cohort of 171 TCs and 68 ACs. Cases were
subdivided into three Ki-67 ranges (<4/4–9/≥10%).
Correlations with clinicopathological data, univariate and
multivariate survival analyses were performed. The major-
ity of cases (61.5%) belonged to the <4% Ki-67 range; 25.1
and 13.4% had a proliferation index of 4–9% and ≥10%,
respectively. The <4% Ki-67 subgroup was significantly
enriched for TCs (83%, p < 0.0001); ACs were more
frequent in the subgroup showing Ki-67 ≥ 10% (75%,
p < 0.0001). A heterogeneous Ki-67 pattern was
preferentially seen in carcinoids with a Ki-67 ≥10% (38%,
p < 0.02). Mean Ki-67 values ≥4 and ≥10% identified
categories of poor prognosis both in terms of disease-free
and overall survival (p = 0.003 and <0.0001). At multivar-
iate analysis, the two thresholds did not retain statistical
significance; however, a Ki-67 ≥ 10% identified a subgroup
of dismal prognosis even within ACs (p = 0.03) at univar-
iate analysis. Here, we describe a subgroup of lung carci-
noids showing brisk proliferation activity within the necro-
sis and/or mitotic count-based categories. These patients
were associated with specific clinicopathological character-
istics, to some extent regardless of histological subtyping.
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Introduction
Carcinoid tumours of the lung are rare primary lesions ac-
counting for 0.2% (atypical carcinoids, AC) to 2% (typical
carcinoids, TC) of resected lung cancers. According to the
2015 WHO classification [1], they make up the morphologi-
cally defined group of neuroendocrine tumour (NETs) based
upon cytological traits, mitotic count and necrosis. Lung
NETs comprise low- to intermediate-grade forms (TCs and
ACs, respectively), clearly segregated from high-grade malig-
nancies, namely large cell NE carcinomas and small cell car-
cinomas. Carcinoid tumours, however, translate into a broad
clinicopathologic spectrum characterized by highly variable
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outcomes, which are currently best stratified according to the
2015 WHO classification and 8th edition TNM staging [1].
Surgery is the best treatment modality choice for both TCs and
ACs [2], with TCs usually exhibiting long life expectancy
with 5- and 10-year survival rate by far over 90% [3].
Conversely, ACs exhibit a more aggressive clinical course
and a 5-year survival rate ranging from 56 to 87%, which is
lower in node positive patients, suggesting that this subgroup
could benefit from some adjuvant treatment [4–8].
In pulmonary NETs, whether biopsy samples or surgical
specimens, no grading system is currently accepted for further
stratifying single tumour entities beyond the pure tumour his-
tological typing. Indeed, the grading system proposed for
gastroenteropancreatic (GEP) NETs does not apply to thoracic
NETs, nor Ki-67 plays a role in tumour classification. In the
2015 WHO classification, the Ki-67 prognostic role is not
established and is considered valuable in biopsy or cytology
samples only [1]. As a matter of fact, several groups have
confirmed the significant prognostic value of Ki-67 in lung
NETs [9], with a 4–5% cut-off being the most widely
employed for the sake of reproducibility and reliability [10]
compared to mitotic count and necrosis, especially when deal-
ing with biopsy specimens [11, 12].
However, in multivariate survival analysis, Ki-67 seems to
add little value to histological typing [13, 14] when a 4–5%
cut-off is adopted, but results from several studies are still
inconclusive. In order to integrate rather than to replace the
histological classificationwith the information stemming from
Ki-67 index determination, Rindi and co-workers have pro-
posed an accurate and innovative grading system for pulmo-
nary NETs (G1 to G3) where mitotic count, necrosis and Ki-
67 index were jointly combined on the basis of lung-specific
cut-off values [15]. At the histological level, only TCs by
morphology turned out G1, while ACs and the LCNEC/
SCLC group crossed G1 to G3 and G2 to G3 categories,
respectively, confirming the inherent heterogeneity in behav-
iour of intermediate- to high-grade lung NETs [15].
In the GEP area, NET-G3 retaining a well-differentiated
morphology but showing proliferation rates consistent with
NE carcinomas, either in the whole tumour or in focal areas
only, have recently been recognized [16, 17]. These tumours
are associated to genetic alterations of well-differentiated tu-
mours, but with a clinical behaviour intermediate between G2
NETs and more conventional NE carcinomas [18–20]. This
phenomenon would identify secondary high-grade NE tu-
mours evolving from pre-existing lower grade carcinoids, as
recently demonstrated in the thymus [21]. In the lung,
LCNECs with carcinoid-like appearance have been identified
[22, 23], but little is known about the clinical impact of carci-
noid tumours, as defined by current diagnostic guidelines,
showing high Ki-67 indices.
Based on these premises, in this study, we sought to inves-
tigate the prevalence of carcinoid tumours showing brisk
proliferation activity and to define whether values and patterns
of Ki-67 labelling alone would allow for a clinically meaning-
ful stratification of a large cohort of lung carcinoids, regardless
of the histological type. This could be propaedeutic to the
identification of low- to intermediate-grade NETs in the lung
that may have the potential to evolve to a higher grade disease,
thus sustaining the paradigm shift to secondary high-grade
NETs even in the lung.
Materials and methods
Cohort and Ki-67 scoring
The pathology files of the AOU Città della Salute e della
Scienza di Torino and San Luigi Hospital were interrogated
for a diagnosis of carcinoid tumour on surgical specimen, and
a total of 239 consecutive specimens were retrieved. All orig-
inal H&E slides were reviewed by four of the authors (CM,
GG, MV, MP) to confirm the diagnostic categorization, in-
cluding re-evaluation of the mitotic count and Ki-67 index,
the latter on newly stained slides (if unavailable or subopti-
mal). The cohort comprised 171 TCs and 68 ACs, defined
according to the WHO 2015 criteria [1]. The study has been
approved by the local ethical committee (Department of
Oncology at San Luigi Hospital, number 17975, October
14th 2015). Discordant cases were discussed at a multi-
headed microscope to reach agreement. We manually scored
Ki-67 labelling index by counting at least 1000 cells. We also
recorded whether the pattern of Ki-67 labelling was homoge-
neous throughout tumour samples or whether hotspot areas
could be clearly identified (heterogeneous Ki-67 pattern).
Whenever hotspot areas were detected, the highest recorded
value was taken into account to perform statistical correlative
analyses. Hotspot areas were defined as foci of tumour cells
selected at lowmagnification (40×) based on an overcrowding
of positive nuclei that led to a much higher count than the
mean Ki-67 index evaluated on the overall tumour cell popu-
lation. No specific cut-offs were adopted to identify hotspots.
This definition allowed to identify areas of heterogeneous
proliferation even within the context of TCs, where a prolif-
eration count as low as 1 to 4% is usually encountered.
A dedicated database was constructed where clinicopatho-
logical features were annotated, including follow-up data.
Statistical analysis
Cases were subdivided according to three different Ki-67
ranges (<4, 4–9, ≥10%) and correlation with histopathological
features; pattern of Ki-67 and follow-up data were performed
by Chi square test. The 4% threshold for Ki-67 is one of the
most frequently adopted in literature [14, 15, 24–26], while
the ≥10% cut-off was chosen based on the mean Ki-67 value
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of 9% observed in this series of AC (otherwise belonging to
the 10–20% range mentioned for carcinoids in the current
WHO classification [1]). A p < 0.05 value was considered
statistically significant. Univariate time to progression and
overall survival analyses were performed with the Kaplan-
Meier method, and the log-rank test was employed to compare
survival curves. Cox proportional hazards regression model
was also used in multivariate survival analysis.
Results
Clinicopathological features
TCs and ACs showed a mean Ki-67 value of 2.8 and 9%,
respectively, ranging from 1 to 18% for TCs and 1 to 43%
for ACs (Fig. 1). Of note, four cases of ACs (1.7% of the total,
5.9% of the ACs) displayed a mean proliferation index of
≥25%.
Stratification of the tumour cohort according to 4 and 10%
Ki-67 cut-off thresholds is shown in Table 1. The large ma-
jority of cases (147/239, 61.5%) pertained to the lowest Ki-67
range (<4%), 60 cases (25.1%) had a proliferation index be-
tween 4 and 9%, and a minor subgroup (32/239, 13.4%)
displayed a Ki-67 labelling index of ≥10%.
The low Ki-67 subgroup (<4%) was significantly enriched
for TCs (122/147, 83%, p < 0.0001, Table 1), whereas ACs
were more frequently found in the subgroup showing a mean
Ki-67 of ≥10% (24/32, 75%, p < 0.0001, Table 1).
Nevertheless, eight cases with a Ki-67 higher than 10% were
classified as TC, according to the morphological criteria. A
homogeneous Ki-67 labelling pattern was a significant feature
of the low (<4%) Ki-67 subgroup (80/93, 86%, p < 0.02,
Table 1, Fig. 2) as well as of the intermediate (4–9%) Ki-67
subgroup (32/40, 80%, p < 0.02, Table 1), whereas a hetero-
geneous Ki-67 pattern was preferentially seen in the subgroup
of carcinoids with a proliferation index of ≥10% (11/29 as-
sessable cases, 38%, p < 0.02, Table 1, Figs. 1 and 2).
Vascular invasion and pleural involvement were relatively
more represented in the carcinoid subgroupwith Ki-67 ≥ 10%,
and the differences among subgroups were statistically signif-
icant (p = 0.001, Table 1).
Patient outcome
Univariate analyses
Patients with a TC diagnosis had an excellent disease-free and
overall survival, which was significantly better compared to
patients affected by ACs (p < 0.0001, Tables 2 and 3, Fig. 3).
When investigating Ki-67, we first dichotomized cases ac-
cording to a 4% cut-off on the whole tumour cohort finding
that it effectively split patients into worse categories in terms
of both disease-free and overall survival for tumours
displaying Ki-67 higher than 4% (p = 0.003, Tables 2 and 3;
Fig. 3). The same held true when stratifying cases by using the
10% cut-off threshold, with two different prognostic popula-
tions for both time to progression and overall survival
(p < 0.0001, Tables 2 and 3). In addition, when the whole
tumour cohort was stratified into three groups according to
the 4 and 10% cut-off thresholds, we observed that outcome
of patients with tumours pertaining to the three relevant Ki-67
Fig. 1 Atypical carcinoids
showing different Ki-67 patterns
(homogenous versus
heterogeneous). ACs with
organoid and trabecular growth
patterns (a and c: H&E 40×, inset
100×) showing a homogenously
(b: 40×) and heterogeneously (d:
40×) increased Ki-67 index, in
both cases up to 12%
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categories (<4, 4–9, ≥10%) was different in terms of both
overall survival and time to progression (p = 0.0052 and
<0.0001, respectively; Table 1 and Fig. 4), with cases
displaying a Ki-67 ≥ 10% running a poorer survival. Of note,
the difference in terms of outcome between the categories of
<4% and 4–9% was not significantly different for either over-
all survival or time to progression (p = 0.40 and p = 0.32,
respectively). Importantly, the ≥10% cut-off was capable of
significantly predicting patients’ outcome in terms of overall
survival (p = 0.03, Fig. 4) even in the sole AC subgroup
(accounting for the largest number of tumours with a relatively
higher Ki-67).
Finally, male sex, G2 Rindi’s grade, presence of vascular
invasion or necrosis, and positive nodal status were signifi-
cantly associated with adverse prognosis at both time to pro-
gression and overall survival.
Multivariate analysis
Male sex, nodal status and histological typing were indepen-
dent prognostic factors at multivariate analysis, whereas the
two Ki-67 cut-off thresholds of ≥4 and ≥10% did not retain
statistical significance upon multivariate analysis (Tables 2
and 3). The subgroup of ACs was not powered enough to
perform a multivariate analysis.
Discussion
In this study, we showed that up to 13% of lung carcinoids
display a Ki-67 proliferation index of ≥10% and that 6% of
ACsmay showKi-67 values around 25%.Most importantly, a
10% cut-off for Ki-67 labelling index provided a clinically
meaningful stratification of carcinoid tumours of the lung
even within the subgroup of ACs, thereby providing evidence
that proliferation index assessed by Ki-67 would add useful
prognostic information to histological subtyping.
Table 1 Clinicopathological
features stratified according to
different classes of proliferation,









Sex M 66 18 16 0.08
F 81 42 16
Age Median 56 55 64 0.45
Histological type TC 122 41 8 <0.0001
AC 25 19 24
pT pT1–2 133 56 26 0.35
pT3–4 14 4 5
pN pN0 113 49 21 0.21
pN+ 28 10 10
Ki-67 pattern Homogeneous 80 32 18 0.02
Heterogeneous 13 8 11
Vascular invasion Present 34 17 17 0.001
Absent 101 33 11
Pleura PL0 100 28 20 0.001
PL+ 3 0 5
Patient status NED/DOC 127 51 20 <0.0001
AWD/DOD 11 5 10
Survival data Median TTP (months) Undefined Undefined 101 0.0052
Median OS (months) 244 Undefined 122 <0.0001
M male, F female, TC typical carcinoid, AC atypical carcinoid, NED no evidence of disease, DOC died of other
unrelated causes, AWD alive with disease, DOD died of disease, OS overall survival, TTP time to progression
Fig. 2 Relative prevalence of Ki-67 pattern (homogeneous versus
heterogeneous distribution) in lung carcinoids. A homogeneous Ki-67
labelling pattern was significantly more represented in the low (<4%) Ki-
67 subgroup (86%, p < 0.02, Chi square test) and in the intermediate (4–9%)
Ki-67 subgroup (80%, p < 0.02, Chi square test), whereas a heterogeneous
Ki-67 pattern was preferentially seen in the subgroup of carcinoids with a
proliferation index of ≥10% (38%, p < 0.02, Chi square test)
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It is currently a matter of debate whether the 2015 WHO
classification [1] is adequate enough to encompass the spec-
trum of lung NETs. This classification has substantially con-
firmed the four categories already crystallized in the two
previous editions: it is solely based on histological parame-
ters [27], and the threshold of 10 mitoses/2 mm2 is the
criterion used to take pulmonary carcinoids apart from NE
carcinomas [1]. Here, we show that the rare group of carci-
noid tumours is biologically heterogeneous, including a sub-
group of lesions with a relatively high proliferative potential
as highlighted by the Ki-67 index. From a classification
standpoint, the even rarer AC category is monolithic (necro-
sis and/or 2 to 10 mitoses/2mm2), even if a cut-off of six
mitoses has been proposed, but not envisaged, to separate
tumours with different life expectation [28]. The only diag-
nostic alternative is the category of high-grade neuroendo-
crine carcinomas, either LCNECs or SCLCs, which is how-
ever ruled out upon mitotic count. Interestingly, even
LCNECs may show morphologic [22, 23] and molecular
[23] features rather akin to ACs, supporting the view of a
grey-zone in lung NETs where a biological continuum could
probably be more effective than categorical criteria for clas-
sification purposes. Most importantly, the optimal treatment
options for ACs after surgery, particularly in the metastatic
setting, are highly debated and variably including close fol-
low-up, systemic therapies different from or comprising plat-
inum or even biological drugs (somatostatin analogues or m-
TOR inhibitors).
Table 2 Univariate and multivariate time to progression survival analysis
Parameter Carcinoids—time to progression survival (#219) ACs—time to progression survival (#58)
Univariate Multivariate Univariate
HR (CI) p HR (CI) p HR (CI) p
Sex (M vs F) 4.015 (1.697–9.785) 0.002 0.12 (0.03–0.44) 0.001 3.424 (1.243–9.430) 0.017
Age (above vs below median) 1.570 (0.664–3.712) 0.3 – – 0.450 (0.155–1.310) 0.14
Histological type (AC vs TC) 55.87 (18.13–172.2) <0.0001 22.90 (4.628–113.34) 0.0001 – –
Rindi’s grade (2 vs 1) 50.01 (11.53–217.0) <0.0001 0.261 (0.066–1035) 0.22 1.193 (0.445–3.199) 0.72
Size (above vs below mean) 1.438 (0.570–3.628) 0.59 – – 1.170 (0.406–3.366) 0.7
Clinical stage (all others vs IA/B) 2.001 (0.792–5050) 0.14 – – 1.703 (0.615–4.716) 0.3
Nodal status (N+ vs N0) 7093 (2327–21.61) 0.0006 3.374 (0.684–13.63) 0.036 1.921 (0.764–5.232) 0.2
Vascular invasion (VI+ vs VI−) 4.709 (1.684–13.16) 0.003 – – 1.634 (0.559–4.776) 0.36
KI-67 (≥4 vs <4) 3.994 (1.58–10.0) 0.003 3.374 (0.684–16.63) 0.13 1.252 (0.450–3.475) 0.66
Ki-67 (≥10%) 17.121 (4.32–68.56) <0.0001 0.767 (0.198–2.95) 0.7 1.772 (0.610–5.108) 0.28
Necrosis (present vs absent) 369 (65.42–2082) <0.0001 2.186 (0.622–7.678) 0.2 2.656 (0.925–7.625) 0.07
Table 3 Univariate and multivariate overall survival analysis
Parameter Carcinoids—overall survival (#219) ACs—overall survival (#58)
Univariate Multivariate Univariate
HR (CI) p HR (CI) p HR (CI) p
Sex (M vs F) 3.429 (1.345–8.740) 0.01 0.526 (0.218–1.271) 0.15 2.477 (0.853–7.187) 0.09
Age (above vs below median) 1.617 (0.665–4.08) 0.28 – – 1.336 (0.435–4.097) 0.6
Histoloigc type (AC vs TC) 39.63 (12.37–127.9) <0.0001 3.029 (0.923–9.939) 0.06 – –
Rindi’s grade (2 vs 1) 40.14 (8.760–183.9) <0.0001 0.383 (0.111–1.441) 0.15 1.325 (0.461–3.828) 0.6
Size (above vs below mean) 7.437 (0.539–3.823) 0.52 – – 1.22 (0.389–3.828) 0.7
Clinical stage (all others vs IA/B) 1.324 (0.486–3.605) 0.3 – – 1.401 (0.450–4.355) 0.6
Nodal status (N+ vs N0) 5.109 (1.503–16.70) 0.007 2.930 (1.161–7.546) 0.02 2.206 (0.733–6.642) 0.16
Vascular invasion (VI+ vs VI−) 7.646 (2.531–23.10) <0.0001 – – 4.128 (1.251–13.63) 0.02
KI-67 (≥4 vs <4) 4.31 (1.624–11.45) 0.003 2.879 (0.837–9.904) 0.09 1.451 (0.49–4.29) 0.5
Ki-67 (≥10%) 36.79 (8.868–152) <0.0001 1.949 (0.629–6.036) 0.24 3.53 (1.128–11.08) 0.03
Necrosis (present vs absent) 281 (46.50–1698) <0.0001 2.004 (0.627–6.411) 0.24 3.094 (0.977–9.793) 0.05
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Based on this evidence, we reasoned that rather than forc-
ing the four-tier histological classification, an approach based
on proliferation activity could be beneficial to best depict the
clinical variety within carcinoid tumours, thereby integrating a
purely histological classification. At present, over 2000 lung
NET cases have been published having Ki-67 investigated as
part of the morphological and phenotypical description [9],
and most of these studies recognize the usefulness of Ki-67
index reporting. A multicentre study on almost 400 cases pro-
posed a grading system for lung NETs incorporating the Ki-67
index alongside mitotic count and necrosis evaluation [15].
In our study, we wanted to ascertain whether Ki-67 alone,
not engaged in a grading system, would allow a prognostic
classification within the category of carcinoid tumours with
the specific aim of identifying a niche of carcinoid tumours
(defined according to the official parameters) having a prolif-
eration index above the expected values. Our results clearly
show a prognostic separation in terms of both overall survival
and time to progression when cut-offs of 4 and 10% are
adopted. Our analysis also revealed that the tumours with
either <4 or 4–9% proliferation indices showed comparable
survival rates, thus suggesting the 10% as a more suitable cut-
off to identify lung carcinoids with a clinically meaningful
brisk proliferation activity.
The adoption of Rindi’s grade (grade 2 versus 1) showed a
significant correlation with outcome in univariate but not in
multivariate analysis. Although also the Ki-67 thresholds here
analysed did not reach statistical significance in multivariate
analysis, it is interesting to note that the 10% cut-off was able
to tease out a category of tumours harbouring dismal progno-
sis evenwithin the restricted category of ACs, whereas Rindi’s
grade did not hold significant prognostic information in this
subset of patients.
Fig. 4 Kaplan-Meier survival curves in lung carcinoids segregated
according to distinct Ki-67 thresholds (4 and 10%). Analysis of
patients’ outcome in terms of overall survival (a) and time to
progression (b) in the whole cohort of lung carcinoids stratified
according to 4 and 10% cut-offs. Of note, the difference in terms of
outcome between the categories of <4 and 4–9% was not statistically
significant for either overall survival or time to progression (p = 0.40
and p = 0.32, respectively). c Subgroup analysis restricted to atypical
carcinoids segregated according to the 10% cut-off, which significantly
predicted the ultimate outcome of patients (p = 0.03) even in the sole
AC histological type
Fig. 3 Kaplan-Meier survival curves in lung carcinoids segregated
according to histological type (a) and Ki-67 > 4% (b). a Patients with a
TC diagnosis had an excellent overall survival, which was significantly
better compared to patients affected by ACs (p < 0.0001). b The 4% cut-
off on the whole tumour cohort effectively split patients into worse
categories for tumours displaying Ki-67 higher than 4% (p = 0.003)
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Importantly, a heterogeneous Ki-67 proliferation pattern
was significantly more common in the category of cases
displaying a Ki-67 labelling index ≥10%. This is in line with
recent reports suggesting that intra-tumour heterogeneity
holds per se a negative prognostic impact, as shown across
several distinct diseases [29].
We documented in our study that a non-negligible number
of life-threatening ACs showed quite unexpected high Ki-67
indices, which overlapped with those reported for LCNECs
[1, 9], even if not fulfilling the relevant mitotic count for this
tumour category. Although Ki-67 levels and mitoses do not
entirely reflect the same cell cycle-associated event, it is
known that pancreatic NETs with discrepant Ki-67 and mitot-
ic indices bear different impacts on tumour grading [30].
Moreover, we speculate that these ACs with high Ki-67 index
could harbour a potential of transition towards LCNECs with
similar molecular profiles, either synchronously or
metachronously, as recently demonstrated in thymus ACs
[21]. Furthermore, a recent study by Simbolo et al. [31] has
also shown that rare lung LCNECs resembling carcinoids har-
bour MEN1 mutations—the most frequent alteration in
ACs—along with TERT, SDHA, RICTOR, PIK3CA, MYCL
and SRC gains are shared with high-grade carcinomas. This
is in line with a paradigm shift, even in the lung, that envisages
the development of secondary high-grade NETs from pre-
existing lower grade NETs, as demonstrated in the thymus
[21]. Regrettably, the numerosity of outlier tumour carcinoids,
i.e. either highly proliferating or harbouring genetic features of
aggressive disease (TP53 mutations, hypermutated profile),
was too limited in the recent study reported by Simbolo
et al. [31] to draw any informative conclusions. In this scenar-
io, it becomes clear that a thorough genomic characterization
focused on a large cohort of highly proliferating carcinoid
tumours in strict comparison with LCNECs and SCLCs is
eagerly awaited.
In conclusion, although the histological subtyping still rep-
resents the cornerstone in lung carcinoid classification, the
inter- and intra-tumour heterogeneity of proliferation indices
together with different clinical behaviour within the same his-
tological subgroups suggest that the current morphology-
based system could be suboptimal for an effective prognostic
stratification and therapy planning. Herein, we indicate that a
subgroup of ACs showed brisk Ki-67 indices within the spec-
trum of allowed mitotic count. These patients were associated
with specific clinical and pathological characteristics, to some
extent regardless of histological subtyping. Preliminary data
obtained by our group in thymus ACs on synchronous and
metachronous lesions suggest that a progression capability of
these lesions may stem form a markedly heterogeneous intra-
tumour distribution of Ki-67 labelling indices. The correct
identification of these tumours is clinically warranted. A thor-
ough molecular characterization of this specific high prolifer-
ative index carcinoid subgroup may uncover the determinants
of their biology and/or progression capacity, as well as iden-
tify biomarkers of potential therapeutic usefulness.
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